Heron Therapeutics, Inc. (NASDAQ:HRTX) Q3 2025 Earnings Call Transcript
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q3 2025 Earnings Call Transcript November 4, 2025Heron Therapeutics, Inc. misses on earnings expectations.
Heron Therapeutics Inc. (HRTX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Rubric Capital Management David Rosen | 29,100,728 | $36,666,917 | +9% | 0.41% |
| 2. | Adage Capital Management Phill Gross And Robert Atchinson | 10,239,225 | $12,901,424 | +31% | 0.02% |
| 3. | Clearline Capital Marc Majzner | 9,712,527 | $12,237,784 | +1034% | 0.56% |
| 4. | Velan Capital Adam Morgan | 8,753,290 | $11,029,145 | +26% | 10.36% |
| 5. | Baker Bros. Advisors Julian Baker And Felix Baker | 4,251,951 | $5,357,458 | 0.04% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.50 | 2,387,225 | $3,580,837.50 | 29,100,728 | 2025-08-08 | Filing | |
| $1.50 | 1,766,546 | $2,649,819.00 | 8,753,290 | 2025-08-08 | Filing | |
| $1.09 | 25,000 | $27,250.00 | 79,000 | 2023-11-17 | Filing | |
| $0.94 | 50,000 | $46,995.00 | 54,000 | 2023-11-16 | Filing | |
| $0.92 | 150,000 | $137,970.00 | 186,496 | 2023-11-16 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.76 | 1,504 | $7,153.63 | 10,872 | 2022-05-03 | Filing | |
| $9.73 | 300 | $2,920.35 | 3,200 | 2021-12-21 | Filing | |
| $9.73 | 250 | $2,431.93 | 2,840 | 2021-12-21 | Filing | |
| $12.31 | 300 | $3,691.95 | 3,500 | 2021-09-21 | Filing | |
| $12.30 | 250 | $3,074.10 | 3,090 | 2021-09-21 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 9,987,460 | $12,584,200 | 0% | |
| 2. | 8,459,784 | $10,659,328 | 0% | |
| 3. | 7,327,447 | $9,232,583 | 0.25% | |
| 4. | 4,589,715 | $5,783,041 | 3.02% | |
| 5. | 3,651,503 | $4,600,894 | 0% |
News See All
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q2 2025 Earnings Call Transcript
Operator: Thank you for standing by, and welcome to the Heron Therapeutics Second Quarter 2025 Earnings Conference Call. [Operator Instructions] As a reminder, today's program is being recorded.
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q1 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Heron Therapeutics Q1 2025 Conference Call. At this time, all participants are in a listen-only mode.
10 Hot Biotech Stocks Under $5
The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing investor attention.
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q4 2024 Earnings Call Transcript
Operator: Good day, and thank you for standing by, and welcome to the Heron Therapeutics Q4 2024 Conference Call. At this time, all participants are in a listen-only mode.
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q3 2024 Earnings Call Transcript
Operator: Thank you for standing by and welcome to Heron Therapeutics Third Quarter 2024 Conference Call. At this time, all participants are in a listen-only mode.
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q2 2024 Earnings Call Transcript
Operator: Thank you for standing by. My name is Jermaine, and I will be your conference operator today. At this time, I would like to welcome everyone to Heron Therapeutics Q2 2024 Conference Call.
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q1 2024 Earnings Call Transcript
Heron Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.0209, expectations were $-0.08.
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q4 2023 Earnings Call Transcript
Operator: Thank you for standing by, and welcome to the Heron Therapeutics Fourth Quarter 2023 Conference Call.
12 Best Rising Penny Stocks To Buy
Stocks are roaring after Nvidia posted yet another strong quarter, crushing AI naysayers who were calling the stock overvalued and the AI wave a hype.